NAFDAC Clinical Trial Approval: Nigeria Guide

Nigeria is one of Africa’s largest clinical trial markets, and every interventional trial conducted there runs through two parallel regulatory gates: a product-level clinical trial approval from the National Agency for Food and Drug Administration and Control (NAFDAC) and an independent ethics clearance from Nigeria’s national or institutional health research ethics system. Since 5 May 2025, NAFDAC’s conduct-of-trial expectations are also governed by an updated Good Clinical Practice framework explicitly aligned to ICH E6(R3). This guide walks through both gates, the 2025 GCP update, and where Nigeria sits in broader African regulatory harmonization.

What NAFDAC Is and Why It Sits at the Center of Nigerian Trial Approval

NAFDAC is Nigeria’s national medicines and food regulatory authority, established by statute to regulate the manufacture, importation, exportation, advertisement, distribution, sale, and use of drugs, cosmetics, medical devices, and related products, including investigational products used in clinical research. Because it controls importation and manufacture, NAFDAC is the agency that determines whether an investigational drug, biologic, or device can legally enter Nigeria or be manufactured locally for use in a trial — a sponsor cannot lawfully import or produce an investigational product for a Nigerian trial site without NAFDAC’s clinical trial approval in hand.

NAFDAC Clinical Trial Approval: The Core Requirement

NAFDAC clinical trial approval is a precondition, not a formality that can run in parallel with shipment. No investigational drug, biologic, vaccine, or device may be imported, procured, or manufactured in Nigeria for use in a clinical trial without a valid clinical trial approval issued by NAFDAC. This mirrors the structure used by most stringent-and-emerging regulatory authorities: the agency reviews the protocol, investigator’s brochure, informed consent materials, product quality/manufacturing information, and evidence of ethics engagement before it will authorize the investigational product to move.

In practice this means the regulatory-approval workstream and the ethics-review workstream (below) need to be planned together, not sequenced as strictly one-then-the-other, since NAFDAC’s review typically expects evidence that ethics review has been initiated or obtained alongside the scientific/product dossier. Sponsors and CROs building a Nigeria site into a multi-country protocol should budget for both tracks from the same start date rather than treating NAFDAC as a final rubber stamp after ethics clearance is already in hand.

Ethics Clearance: NHREC and Institutional HRECs

Nigeria’s ethics oversight runs through the National Health Research Ethics Committee (NHREC), the apex body established under Nigeria’s health research governance framework to register and accredit institutional Health Research Ethics Committees (HRECs) across the country and to provide national-level ethics oversight for human subjects research. A Nigerian clinical trial needs a documented ethics clearance from NHREC or from an NHREC-registered institutional HREC at the site(s) where the research will be conducted, in addition to — not instead of — NAFDAC’s product-level clinical trial approval.

This dual-track structure (a national regulatory authority for the product, a separate ethics-committee system for the human-subjects protections) is the same basic architecture used across most jurisdictions with mature clinical trial oversight, though the specific institutions and their division of labor differ country to country — see the sibling guides linked at the end of this page for how other jurisdictions structure the equivalent split.

The 2025 GCP Guidelines and Alignment with ICH E6(R3)

NAFDAC published an updated Good Clinical Practice Guidelines document in 2025, effective 5 May 2025, replacing its prior GCP guidance. The update is explicitly framed around alignment with the International Council for Harmonisation’s revised core GCP guideline, ICH E6(R3), which itself reached ICH Step 4 (finalization) on 6 January 2025 before regional regulators began setting their own implementation and effective dates — the EMA set 23 July 2025 for the Principles and Annex 1 in the EU, and the FDA issued its own final E6(R3) guidance on 8 September 2025.

For sponsors already building ICH E6(R3)-aligned quality systems for other jurisdictions — the risk-proportionate, quality-by-design approach to trial oversight and the more explicit data-governance expectations that distinguish E6(R3) from the 2016 E6(R2) addendum — NAFDAC’s 2025 update signals that the same core GCP documentation and quality-management approach should extend to a Nigerian site without needing a materially different oversight model built specifically for Nigeria. It does not, however, eliminate the need to confirm Nigeria-specific procedural detail (forms, timelines, local-language informed consent requirements, and NAFDAC’s own submission channel) directly against NAFDAC’s published guideline text before filing, since a regional GCP update aligning with an international guideline is a statement of principles-level alignment, not a guarantee that every procedural detail matches ICH E6(R3) verbatim.

PIC/S Engagement and GMP Oversight

Separately from clinical trial approval, NAFDAC’s manufacturing/quality oversight function has been moving toward closer alignment with the Pharmaceutical Inspection Co-operation Scheme (PIC/S), the international framework that harmonizes Good Manufacturing Practice (GMP) inspection standards among its member regulatory authorities. NAFDAC has engaged with PIC/S as part of a broader wave of African national regulatory authorities pursuing closer ties to the scheme, participating in PIC/S proceedings alongside other African NRAs working through PIC/S’s pre-accession process. Full PIC/S participating-authority status is a multi-year process contingent on demonstrating a GMP inspection system judged comparable to PIC/S standards; sponsors should confirm NAFDAC’s current PIC/S status directly against PIC/S’s own published member list rather than relying on a point-in-time summary, since this status is actively evolving.

AMRH and Regional Harmonization

Nigeria and NAFDAC also participate in the African Medicines Regulatory Harmonization (AMRH) initiative, a programme run under the African Union Development Agency (AUDA-NEPAD) as part of the continent’s broader Pharmaceutical Manufacturing Plan for Africa. AMRH works through Africa’s regional economic communities — Nigeria’s track runs through the Economic Community of West African States (ECOWAS) — to harmonize registration requirements, inspection standards, and clinical trial oversight practices across member states, reducing the extent to which a sponsor running trials across multiple West African countries needs an entirely distinct regulatory strategy for each one. For a sponsor scoping a multi-country West African trial, AMRH-driven harmonization is a reason to expect increasing procedural convergence with neighboring markets over time, even though NAFDAC’s national clinical trial approval and NHREC/HREC ethics clearance remain the two approvals a Nigerian site specifically requires.

Practical Checklist for Sponsors Planning a Nigerian Site

Confirm the current NAFDAC clinical trial application requirements and dossier checklist directly from NAFDAC’s own published guidance before finalizing a submission timeline — regulatory dossiers and forms are revised periodically.
Initiate ethics review with NHREC or an NHREC-registered institutional HREC in parallel with, not after, the NAFDAC regulatory submission.
Build the trial’s GCP quality-management approach around ICH E6(R3) principles from the outset if the study spans multiple ICH-aligned jurisdictions, since Nigeria’s 2025 GCP update now points the same direction.
Do not import, procure, or locally manufacture investigational product for the Nigerian site until NAFDAC’s clinical trial approval has actually been issued — this is a hard precondition, not a step that can run concurrently with shipment.
Track NAFDAC’s evolving PIC/S status and AMRH/ECOWAS harmonization activity if the same investigational product and quality system will support sites in other West African markets.

Frequently Asked Questions

Does NAFDAC approval replace the need for ethics committee clearance in Nigeria?

No. NAFDAC’s clinical trial approval and ethics clearance from NHREC or an NHREC-registered institutional HREC are separate, both-required approvals. NAFDAC reviews the product and protocol from a regulatory/quality-and-safety standpoint; the ethics committee reviews the study’s human-subjects protections. A Nigerian trial needs both before it can proceed.

When did NAFDAC’s updated GCP Guidelines take effect?

NAFDAC’s 2025 Good Clinical Practice Guidelines took effect on 5 May 2025, replacing NAFDAC’s prior GCP guidance and explicitly framed around alignment with ICH E6(R3).

Is NAFDAC a full PIC/S member?

NAFDAC has been engaging with PIC/S as part of the pre-accession process alongside other African regulatory authorities pursuing membership, rather than holding confirmed long-standing full participating-authority status. Because this status can change, confirm NAFDAC’s current standing directly against PIC/S’s own published member list before treating it as a settled fact in a regulatory submission.

Can an investigational product be shipped to Nigeria before NAFDAC approval is issued?

No. Importing, procuring, or manufacturing an investigational drug, biologic, or device in Nigeria for use in a clinical trial without a valid NAFDAC clinical trial approval is not permitted.

Related Country Regulatory Pathway Guides

This guide is part of CASRAI’s series on national clinical trial regulatory pathways. See also:

For the underlying international standard referenced throughout NAFDAC’s 2025 update, see CASRAI’s entry on ICH E6(R3), and for the predecessor guideline still in active use elsewhere, ICH E6(R2).